September 23, 2024
Appeals Court Revives PhRMA’s Challenge to IRA’s Medicare Drug Price Negotiation Program
PhRMA, Inflation Reduction Act, Medicare Drug Price Negotiation Program, Fifth Circuit Court of Appeals, drug pricing, healthcare litigation
Bristol Myers Squibb Continues Layoffs, Cutting 79 More Jobs in New Jersey Amid $1.5B Cost Reduction Effort
Bristol Myers Squibb, layoffs, New Jersey, cost reduction, pharmaceutical industry
Athira Pharma Shifts Focus to ALS After Alzheimer’s Setback, Cuts 70% of Workforce
Athira Pharma, Alzheimer’s disease, ALS, layoffs, biotech, neurodegenerative diseases, small molecule therapy
BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis
KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.
Eli Lilly and Novo Nordisk Support OAC’s Your Weight Matters Campaign Amidst Competitive Weight Loss Drug Market
Eli Lilly, Novo Nordisk, OAC, Your Weight Matters, weight loss drugs, GLP-1, obesity care, pharmaceutical industry
Zevra Therapeutics Secures FDA Approval for Miplyffa, a Breakthrough Treatment for Niemann-Pick Disease Type C
Zevra Therapeutics, Miplyffa, FDA Approval, Niemann-Pick Disease Type C, Rare Lysosomal Storage Disorder, Arimoclomol
FDA Approves AstraZeneca’s FluMist as First Self-Administered Flu Vaccine
FluMist, self-administered flu vaccine, FDA approval, AstraZeneca, nasal spray vaccine
Sarclisa Gains FDA Approval as First-Line Treatment for Newly Diagnosed Multiple Myeloma
Sarclisa, FDA approval, first-line treatment, multiple myeloma, Sanofi, isatuximab, VRd combination therapy.
FDA Approves AstraZeneca’s FluMist as First Self-Administered Flu Vaccine
FluMist, AstraZeneca, FDA, self-administered flu vaccine, nasal spray influenza vaccine, flu prevention, influenza disease, vaccine accessibility
Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun
Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta